Sign up to save your podcasts
Or
Share 5.13.25: Stelara/Actemra Biosimilar Transition, 2024 Top Spend Drugs, Guest Advantage Update, and Commercial Pediatric Dental Invoice Issue
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
5.13.25: Stelara/Actemra Biosimilar Transition, 2024 Top Spend Drugs, Guest Advantage Update, and Commercial Pediatric Dental Invoice Issue
Welcome to the AmeriHealth Market EdgeCast!
In this episode, we'll cover four key topics from the Market Edge newsletter, summarizing the past month's key articles: Stelara/Actemra Biosimilar Transition, 2024 Top Spend Drugs, Guest Advantage Update, and Commercial Pediatric Dental Invoice Issue.
Check out the links below for the full Market Edge articles on this week's selected topics.
Story 1: Stelara/Actemra Biosimilar Transition
Story 2: 2024 Top Spend Drugs
Story 3: Guest Advantage Update
Story 4: Commercial Pediatric Dental Invoice Issue
View all episodes
By AmeriHealthWelcome to the AmeriHealth Market EdgeCast!
In this episode, we'll cover four key topics from the Market Edge newsletter, summarizing the past month's key articles: Stelara/Actemra Biosimilar Transition, 2024 Top Spend Drugs, Guest Advantage Update, and Commercial Pediatric Dental Invoice Issue.
Check out the links below for the full Market Edge articles on this week's selected topics.
Story 1: Stelara/Actemra Biosimilar Transition
Story 2: 2024 Top Spend Drugs
Story 3: Guest Advantage Update
Story 4: Commercial Pediatric Dental Invoice Issue